151 related articles for article (PubMed ID: 24034420)
21. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.
Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee PA
J Thromb Haemost; 2008 Sep; 6(9):1565-70. PubMed ID: 18564219
[TBL] [Abstract][Full Text] [Related]
22. Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin.
Singh S; Houng AK; Reed GL
Blood; 2019 Sep; 134(12):970-978. PubMed ID: 31395599
[TBL] [Abstract][Full Text] [Related]
23. Decrease in matrix metalloproteinase‑3 activity in systemic sclerosis fibroblasts causes α2‑antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
Niwa H; Kanno Y; Shu E; Seishima M
Mol Med Rep; 2020 Oct; 22(4):3001-3007. PubMed ID: 32945390
[TBL] [Abstract][Full Text] [Related]
24. Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.
Lee KN; Tae WC; Jackson KW; Kwon SH; McKee PA
Blood; 1999 Jul; 94(1):164-71. PubMed ID: 10381509
[TBL] [Abstract][Full Text] [Related]
25. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Wong PF; Gall MG; Bachovchin WW; McCaughan GW; Keane FM; Gorrell MD
Peptides; 2016 Jan; 75():80-95. PubMed ID: 26621486
[TBL] [Abstract][Full Text] [Related]
26. Effect of α2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Baráth B; Bogáti R; Miklós T; Kállai J; Mezei ZA; Bereczky Z; Muszbek L; Katona É
Thromb Res; 2021 Jul; 203():110-116. PubMed ID: 33992873
[TBL] [Abstract][Full Text] [Related]
27. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
Hersch SL; Kunelis T; Francis RB
Blood; 1987 May; 69(5):1315-9. PubMed ID: 2436684
[TBL] [Abstract][Full Text] [Related]
28. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
29. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
Cimminiello C; Soncini M; Gerosa MC; Toschi V; Motta A; Bonfardeci G
Biomed Pharmacother; 1995; 49(7-8):364-8. PubMed ID: 8562864
[TBL] [Abstract][Full Text] [Related]
31. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
32. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin.
Law RH; Sofian T; Kan WT; Horvath AJ; Hitchen CR; Langendorf CG; Buckle AM; Whisstock JC; Coughlin PB
Blood; 2008 Feb; 111(4):2049-52. PubMed ID: 18063751
[TBL] [Abstract][Full Text] [Related]
33. Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis.
Saito H; Goodnough LT; Boyle JM; Heimburger N
Am J Med; 1982 Aug; 73(2):179-82. PubMed ID: 7114073
[TBL] [Abstract][Full Text] [Related]
34. alpha2-antiplasmin is associated with the progression of fibrosis.
Kanno Y; Kawashita E; Minamida M; Kaneiwa A; Okada K; Ueshima S; Matsuo O; Matsuno H
Am J Pathol; 2010 Jan; 176(1):238-45. PubMed ID: 20008146
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report.
Sugioka K; Kodama A; Yoshida K; Okada K; Fukuda M; Shimomura Y
BMC Ophthalmol; 2012 Nov; 12():60. PubMed ID: 23190581
[TBL] [Abstract][Full Text] [Related]
36. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
Urano T; Ihara H; Takada Y; Fujie M; Takada A
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
[TBL] [Abstract][Full Text] [Related]
37. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).
Kanno Y; Kawashita E; Kokado A; Okada K; Ueshima S; Matsuo O; Matsuno H
Arthritis Rheum; 2013 Feb; 65(2):492-502. PubMed ID: 23124680
[TBL] [Abstract][Full Text] [Related]
38. Bradykinin in the ascitic fluid of patients with liver cirrhosis.
Cugno M; Salerno F; Nussberger J; Bottasso B; Lorenzano E; Agostoni A
Clin Sci (Lond); 2001 Dec; 101(6):651-7. PubMed ID: 11724653
[TBL] [Abstract][Full Text] [Related]
39. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.
Tsurupa G; Yakovlev S; McKee P; Medved L
Biochemistry; 2010 Sep; 49(35):7643-51. PubMed ID: 20687529
[TBL] [Abstract][Full Text] [Related]
40. Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Takahashi R; Ono K; Ikeda T; Akagi A; Noto D; Nozaki I; Sakai K; Asakura H; Iwasa K; Yamada M
Amyloid; 2012 Sep; 19(3):129-32. PubMed ID: 22624582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
